93M1 Stock Overview
MPH Health Care AG, an investment company engages in the healthcare business in Germany.
MPH Health Care Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€20.60|
|52 Week High||€31.20|
|52 Week Low||€19.65|
|1 Month Change||-6.79%|
|3 Month Change||-11.59%|
|1 Year Change||-21.07%|
|3 Year Change||-47.32%|
|5 Year Change||-43.65%|
|Change since IPO||-11.29%|
Recent News & Updates
|93M1||DE Pharmaceuticals||DE Market|
Return vs Industry: 93M1 underperformed the German Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: 93M1 underperformed the German Market which returned -11.4% over the past year.
|93M1 Average Weekly Movement||7.3%|
|Pharmaceuticals Industry Average Movement||6.4%|
|Market Average Movement||6.4%|
|10% most volatile stocks in DE Market||10.8%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: 93M1 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 93M1's weekly volatility (7%) has been stable over the past year.
About the Company
MPH Health Care AG, an investment company engages in the healthcare business in Germany. It produces and sells medicinal products for the therapies of cancer, HIV, and other chronic diseases. The company also offers medical aesthetic treatments; and develops and sells pharmaceutical and medical products; and provides related services, as well as medical devices for the aesthetic surgery and cosmetic dermatology.
MPH Health Care Fundamentals Summary
|93M1 fundamental statistics|
Is 93M1 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|93M1 income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
May 24, 2022
|Earnings per share (EPS)||-3.33|
|Net Profit Margin||-64.76%|
How did 93M1 perform over the long term?See historical performance and comparison
Is MPH Health Care undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 93M1 (€20.6) is trading below our estimate of fair value (€71.49)
Significantly Below Fair Value: 93M1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 93M1 is unprofitable, so we can't compare its PE Ratio to the German Pharmaceuticals industry average.
PE vs Market: 93M1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 93M1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 93M1 is good value based on its PB Ratio (0.4x) compared to the DE Pharmaceuticals industry average (2.7x).
How is MPH Health Care forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 93M1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).
Earnings vs Market: 93M1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 93M1's is expected to become profitable in the next 3 years.
Revenue vs Market: 93M1's revenue (39.4% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: 93M1's revenue (39.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 93M1's Return on Equity is forecast to be high in 3 years time
How has MPH Health Care performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 93M1 is currently unprofitable.
Growing Profit Margin: 93M1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 93M1 is unprofitable, and losses have increased over the past 5 years at a rate of 62.4% per year.
Accelerating Growth: Unable to compare 93M1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 93M1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.1%).
Return on Equity
High ROE: 93M1 has a negative Return on Equity (-6.35%), as it is currently unprofitable.
How is MPH Health Care's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 93M1's short term assets (€3.3M) exceed its short term liabilities (€1.5M).
Long Term Liabilities: 93M1's short term assets (€3.3M) do not cover its long term liabilities (€5.0M).
Debt to Equity History and Analysis
Debt Level: 93M1 has more cash than its total debt.
Reducing Debt: 93M1's debt to equity ratio has reduced from 4.6% to 1.3% over the past 5 years.
Debt Coverage: 93M1's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 93M1's interest payments on its debt are well covered by EBIT (90.6x coverage).
What is MPH Health Care current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 93M1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 93M1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 93M1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 93M1's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 93M1 is not paying a notable dividend for the German market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 93M1 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Mr. Patrick Brenske has been Chief Executive Officer of MPH Health Care AG (formerly known as MPH Mittelständische Pharma Holding AG) since January 23, 2009 and has been its Member of Management Board sinc...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MPH Health Care AG's employee growth, exchange listings and data sources
- Name: MPH Health Care AG
- Ticker: 93M1
- Exchange: DB
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €88.197m
- Shares outstanding: 4.28m
- Website: https://www.mph-ag.de
Number of Employees
- MPH Health Care AG
- Grünauer Straße 5
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.